Chemically modified mRNA beyond COVID-19: Potential preventive and therapeutic applications for targeting chronic diseases.
Biological Availability
COVID-19
/ prevention & control
Chronic Disease
/ prevention & control
Drug Carriers
Forecasting
Gene Transfer Techniques
Genetic Therapy
/ methods
Genetic Vectors
/ administration & dosage
Humans
Immunotherapy
/ methods
Immunotherapy, Active
Nanoparticle Drug Delivery System
Pandemics
/ prevention & control
RNA Stability
RNA, Messenger
/ administration & dosage
SARS-CoV-2
/ genetics
Vaccine Development
Vaccines, Synthetic
/ administration & dosage
mRNA Vaccines
/ administration & dosage
COVID-19
Cancer
Chemically Modified mRNA
Chronic diseases
Diabetes
Vaccination
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
30
08
2021
revised:
19
10
2021
accepted:
25
10
2021
entrez:
17
12
2021
pubmed:
18
12
2021
medline:
24
12
2021
Statut:
ppublish
Résumé
Chemically modified mRNA represents a unique, efficient, and straightforward approach to produce a class of biopharmaceutical agents. It has been already approved as a vaccination-based method for targeting SARS-CoV-2 virus. The COVID-19 pandemic has highlighted the prospect of synthetic modified mRNA to efficiently and safely combat various diseases. Recently, various optimization advances have been adopted to overcome the limitations associated with conventional gene therapeutics leading to wide-ranging applications in different disease conditions. This review sheds light on emerging directions of chemically modified mRNAs to prevent and treat widespread chronic diseases, including metabolic disorders, cancer vaccination and immunotherapy, musculoskeletal disorders, respiratory conditions, cardiovascular diseases, and liver diseases.
Identifiants
pubmed: 34915673
pii: S0753-3322(21)01169-0
doi: 10.1016/j.biopha.2021.112385
pmc: PMC8552589
pii:
doi:
Substances chimiques
Drug Carriers
0
Nanoparticle Drug Delivery System
0
RNA, Messenger
0
Vaccines, Synthetic
0
mRNA Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
112385Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Références
PLoS One. 2015 Jul 01;10(7):e0131128
pubmed: 26131765
Biomed Res Int. 2019 Jan 15;2019:3915851
pubmed: 30766883
Int J Mol Sci. 2017 Jul 03;18(7):
pubmed: 28671607
Mol Ther. 2021 May 5;29(5):1744-1757
pubmed: 33545360
Mol Cancer. 2021 Feb 16;20(1):33
pubmed: 33593376
Mol Cell Biol. 2006 Mar;26(6):2419-29
pubmed: 16508016
J Exp Med. 1996 Aug 1;184(2):465-72
pubmed: 8760800
Immunity. 2005 Aug;23(2):165-75
pubmed: 16111635
Cell Res. 2013 Oct;23(10):1172-86
pubmed: 24018375
Sci Rep. 2018 Nov 30;8(1):17509
pubmed: 30504800
J Immunother Cancer. 2015 Apr 21;3:14
pubmed: 25901286
J Indian Prosthodont Soc. 2013 Mar;13(1):2-6
pubmed: 24431699
Mol Ther. 2008 Nov;16(11):1833-40
pubmed: 18797453
J Am Coll Cardiol. 2017 Jul 4;70(1):1-25
pubmed: 28527533
EFORT Open Rev. 2017 Jul 27;2(7):332-342
pubmed: 28828182
Nature. 2020 Oct;586(7830):578-582
pubmed: 32731258
J Funct Biomater. 2018 Jan 13;9(1):
pubmed: 29342830
J Gene Med. 2013 Nov-Dec;15(11-12):414-26
pubmed: 24123772
RNA Biol. 2012 Jun;9(6):828-42
pubmed: 22617878
J Immunother. 2008 Feb-Mar;31(2):180-8
pubmed: 18481387
Virus Res. 2020 Oct 15;288:198114
pubmed: 32800805
Front Pediatr. 2019 Jun 18;7:246
pubmed: 31275909
Trends Mol Med. 2014 Nov;20(11):604-13
pubmed: 25263172
Cell Med. 2014 May 02;7(1):15-24
pubmed: 26858889
Nucleic Acids Res. 2016 Nov 16;44(20):9578-9590
pubmed: 27903882
Mol Pharm. 2015 Mar 2;12(3):991-6
pubmed: 25588055
Cold Spring Harb Perspect Biol. 2016 Jun 01;8(6):
pubmed: 27252362
Cardiovasc Drugs Ther. 2020 Dec;34(6):871-880
pubmed: 32822006
EClinicalMedicine. 2021 Jan;31:100689
pubmed: 33392485
J Hepatol. 2021 Jun;74(6):1416-1428
pubmed: 33340584
Sci Rep. 2020 Apr 27;10(1):7052
pubmed: 32341402
Tissue Eng Part A. 2019 Jan;25(1-2):113-120
pubmed: 29676227
Intractable Rare Dis Res. 2018 May;7(2):73-78
pubmed: 29862147
J Vis Exp. 2014 Nov 13;(93):e51943
pubmed: 25489992
Orphanet J Rare Dis. 2009 Jan 08;4:1
pubmed: 19133130
Mol Cancer. 2021 Apr 15;20(1):69
pubmed: 33858437
Sci Rep. 2018 Jan 30;8(1):1843
pubmed: 29382859
Front Cell Dev Biol. 2014 Nov 12;2:67
pubmed: 25429365
BMC Surg. 2020 Feb 12;20(1):31
pubmed: 32050952
PLoS One. 2015 Sep 18;10(9):e0138375
pubmed: 26381750
Int J Biochem Cell Biol. 2012 Mar;44(3):465-8
pubmed: 22155301
Sports Health. 2012 May;4(3):193-201
pubmed: 23016086
Cancer Res. 1995 Apr 1;55(7):1397-400
pubmed: 7882341
N Engl J Med. 2020 Jun 18;382(25):2469-2471
pubmed: 32558474
Mol Ther. 2010 Dec;18(12):2112-20
pubmed: 20628358
Sci Rep. 2016 Jan 05;6:18743
pubmed: 26728350
Genome Med. 2017 Jun 27;9(1):60
pubmed: 28655327
Nat Rev Drug Discov. 2014 Oct;13(10):759-80
pubmed: 25233993
PLoS One. 2017 Aug 9;12(8):e0182738
pubmed: 28793336
Genes (Basel). 2019 Jan 29;10(2):
pubmed: 30699960
J Control Release. 2016 Oct 10;239:137-48
pubmed: 27586186
PeerJ. 2018 May 11;6:e4370
pubmed: 29770269
J Clin Invest. 2013 Mar;123(3):1216-28
pubmed: 23391720
Mol Pharm. 2021 Mar 1;18(3):1121-1137
pubmed: 33492959
Folia Biol (Praha). 2019;65(3):109-123
pubmed: 31638558
Nat Rev Genet. 2015 Jan;16(1):45-56
pubmed: 25404111
Commun Biol. 2021 Jan 19;4(1):82
pubmed: 33469143
N Engl J Med. 2021 Sep 23;385(13):1172-1183
pubmed: 34192426
Tissue Eng Part A. 2019 Jan;25(1-2):131-144
pubmed: 30009674
Nature. 2015 Mar 19;519(7543):366-9
pubmed: 25762141
Mol Ther. 2018 Aug 1;26(8):2034-2046
pubmed: 29910178
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Anticancer Res. 2010 Dec;30(12):5091-7
pubmed: 21187495
World J Clin Cases. 2015 Jan 16;3(1):52-7
pubmed: 25610850
Nat Rev Drug Discov. 2018 Apr;17(4):261-279
pubmed: 29326426
Nat Commun. 2019 Feb 20;10(1):871
pubmed: 30787295
Korean J Intern Med. 2018 May;33(3):453-461
pubmed: 29462546
Circulation. 2020 Apr 14;141(15):1249-1265
pubmed: 32078387
Appl Clin Genet. 2021 Mar 22;14:173-194
pubmed: 33790624
J Immunother Cancer. 2015 Jun 16;3:26
pubmed: 26082837
J Nucleic Acids. 2018 Jun 13;2018:8247935
pubmed: 30009048
PLoS One. 2016 Apr 21;11(4):e0154001
pubmed: 27101288
Mol Ther Nucleic Acids. 2017 Jun 16;7:350-365
pubmed: 28624211
Stem Cells Dev. 2017 Jan 1;26(1):25-34
pubmed: 27676276
Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13824-9
pubmed: 20631300
Lancet Infect Dis. 2021 Feb;21(2):181-192
pubmed: 33217362
Cell Rep. 2018 Aug 28;24(9):2520
pubmed: 30157442
Signal Transduct Target Ther. 2020 Jan 3;5(1):1
pubmed: 32296011
Cell Mol Life Sci. 2017 Jan;74(1):93-115
pubmed: 27714410
Life Sci Alliance. 2019 Dec 16;3(1):
pubmed: 31843959
Adv Sci (Weinh). 2021 Mar 12;8(10):2004661
pubmed: 34026458
Nat Struct Mol Biol. 2018 May;25(5):357-364
pubmed: 29662218
Nat Biotechnol. 2013 Oct;31(10):898-907
pubmed: 24013197
Pharmaceutics. 2020 Jan 28;12(2):
pubmed: 32013049
Front Immunol. 2019 Mar 27;10:594
pubmed: 30972078
Eur Cell Mater. 2017 May 24;33:294-307
pubmed: 28537650
Gene Ther. 2005 Jun;12(11):881-90
pubmed: 15908994
J Bras Pneumol. 2013 Jun-Aug;39(4):409-17
pubmed: 24068261
Nat Commun. 2021 Jan 27;12(1):613
pubmed: 33504774
Nat Rev Genet. 2011 May;12(5):329-40
pubmed: 21499294
Appl Clin Genet. 2012 May 29;5:29-36
pubmed: 23776378
Arthritis Rheum. 2012 Jun;64(6):1697-707
pubmed: 22392533
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
J Orthop Res. 2002 Nov;20(6):1352-7
pubmed: 12472252
Int J Stem Cells. 2011 Jun;4(1):1-8
pubmed: 24298328
Mol Ther Methods Clin Dev. 2020 Jun 01;18:464-472
pubmed: 32728595
Mol Ther Nucleic Acids. 2018 Sep 7;12:530-542
pubmed: 30195789
Stem Cells Transl Med. 2016 Nov;5(11):1525-1537
pubmed: 27405779